Fennec Pharmaceuticals Inc. has reported an impressive earnings surprise, showcasing its growth trajectory in the biotechnology sector.
On August 11, 2026, Fennec Pharmaceuticals Inc. (FRX.TO) announced its latest earnings results for the fiscal period ending June 30, 2026. The company delivered a remarkable earnings per share (EPS) of $0.0697, significantly surpassing the analyst estimate of $0.02. This 248.5% surprise marks Fennec's third earnings beat in the last four quarters, further solidifying its position in the biotechnology market.
Recent earnings trend
Advertisement
Fennec Pharmaceuticals Inc
FRX.TO
FRX.TO
Fennec Pharmaceuticals Inc
WealthAwesomeAdvertisement
Market cap
$556.49M
52W high
$17.64
52W low
$7.59
1W change
+27.29%
Beta
1.07
Analyst Price Targets
Based on analyst covering FRX
Wall Street analysts forecast FRX stock price to rise 430.7% over the next 12 months.
Consensus
BullishBased on avg. target vs last close (formal rating unavailable for Canadian listings)
Avg. Target
C$93.57
+430.7% Upside
Current Price
C$17.63
Last close
Analyst ratings and price targets are updated periodically. Not financial advice.
Advertisement
Wealth Awesome Price Forecast
WA ModelStatistical 90-day price range based on FRX's historical volatility
30-Day Vol
59.7%
Annualized
90-Day Vol
79.2%
Annualized
Trend (90d)
+50.0%
Annualized drift
90d Mean
C$21.08
Expected price
| Horizon | Expected | 68% Range (1σ) |
|---|---|---|
| 30 trading days | C$18.71 | C$15.23 – C$22.99 |
| 60 trading days | C$19.86 | C$14.84 – C$26.57 |
| 90 trading days | C$21.08 | C$14.76 – C$30.10 |
Methodology: Range is calculated using 30-day realized volatility via geometric Brownian motion (log-normal model). 68% band = ±1σ, 95% band = ±2σ. This is a statistical model, not a prediction. Past volatility does not guarantee future results. Not financial advice.
Analyst coverage: 6 analyst(s) cover this name; upcoming EPS consensus is available.
Beat estimates in 3 of the last 4 comparable quarter(s).
| Fiscal period | Report date | Actual EPS | Estimate | Surprise |
|---|---|---|---|---|
| 2026-06-30 | 2026-08-11 | 0.0697 | 0.0200 | +248.5% |
| 2026-03-31 | 2026-05-14 | 0.0137 | -0.0200 | +168.5% |
| 2025-12-31 | 2026-03-24 | -0.1400 | 0.0500 | -380.0% |
| 2025-09-30 | 2025-11-13 | -0.0300 | -0.0400 | +25.0% |
| 2025-06-30 | 2025-08-14 | -0.1500 | -0.0400 | -275.0% |
| 2025-03-31 | 2025-05-13 | -0.0600 | -0.1200 | +50.0% |
Advertisement
Investor takeaway: Fennec's strong performance not only highlights its operational efficiency but also reflects growing investor confidence, especially given its bullish analyst ratings and substantial upside potential in price targets.
Bull case
Fennec Pharmaceuticals is showing solid growth, backed by its earnings surprises and rising product sales, particularly with its flagship product, PEDMARK®. The recent earnings report indicates that the company is effectively navigating a competitive landscape and could see further revenue growth as it expands its market presence.
Bear case
Despite the positive earnings report, Fennec Pharmaceuticals has experienced volatility in the past, including a significant earnings miss in December 2025. Investors should stay cautious of potential market fluctuations and the inherent risks associated with biotech investments.
Advertisement
Advertisement
Wealth Awesome
Timely coverage of Canadian stocks, earnings, dividends, and market movers for DIY investors. Stories are checked against exchange data and public filings.
View Full Profile →✅ Reviewed by Certified Financial Professionals
This content has been reviewed by CFA® charterholders and Certified Financial Planners (CFP®) with over a decade of experience in Canadian financial markets. All information is fact-checked against official Canadian sources and regulations.
Why these credentials matter: CFA® charterholders complete 900+ hours of rigorous study in investment analysis and ethics. CFP® professionals are held to the highest standards of financial planning competency and fiduciary duty in Canada.
⚠️ Professional Disclaimer
This content is for educational purposes only and should not be considered personalized financial advice. While our team brings professional expertise, individual circumstances vary. For personalized guidance, consult with a qualified financial advisor, tax professional, or mortgage specialist.
